Homework Help is Here – Start Your Trial Now!
Business
Finance
Estimate Pharma’s sustainable sales growth rate based on its 2019 financial statements. [Hint: You need to estimate the beginning of period stockholders’ equity based on the information provided.] What financial policy change might Pharma Biotech make to improve its sustainable growth rate? Show your calculations

Estimate Pharma’s sustainable sales growth rate based on its 2019 financial statements. [Hint: You need to estimate the beginning of period stockholders’ equity based on the information provided.] What financial policy change might Pharma Biotech make to improve its sustainable growth rate? Show your calculations

Essentials Of Investments
Essentials Of Investments
11th Edition
ISBN:9781260013924
Author:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Chapter1: Investments: Background And Issues
Section: Chapter Questions
Problem 1PS
See similar textbooks
icon
Related questions
Question
Estimate Pharma’s sustainable sales growth rate based on its 2019 financial statements. [Hint: You need to estimate the beginning of period stockholders’ equity based on the information provided.] What financial policy change might Pharma Biotech make to improve its sustainable growth rate? Show your calculations.
Pharma Biotech Corporation The Pharma Biotech Corporation spent several years working on developing a DHA product that can be used to provide a fatty-acid supplement to a variety of food products. DHA stands for docosahexaenoic acid, an omega-3 fatty acid found naturally in cold-water fish. The benefits of fatty fish oil have been cited in studies of the brain, the eyes, and the immune system. Unfortunately, it is difficult to consume enough fish to get the benefits of DHA, and most individuals might be concerned about the taste consequences associated with adding fatty fish oil to eggs, ice cream, or chocolate candy. To counter these constraints, Pharma Biotech and several competitors have been able to grow algae and other plants that are rich in DHA. The resulting chemical compounds then are used to enhance a variety of food products. Pharma Biotech's initial DHA product was designed as an additive to dairy products and yogurt. For example, the venture's DHA product was added to cottage cheese and fruit-flavored yogurts to enhance the health benefits of those products. After the long product development period, Pharma Biotech began operations in 2018. Income statement and balance sheet results for 2019, the first full year of operations, have been prepared. Pharma Biotech, however, is concerned about forecasting its financial statements for next year because it is uncer- tain about the amount of additional financing for assets that will be needed as Pharma Biotech Corporation the venture ramps up sales. Pharma Biotech expects to introduce a DHA product that can be added to chocolate candies. Not only will consumers get the satisfaction of the taste of the chocolate candies, but they will also benefit from the DHA enhancement. Because this is anticipated to be a blockbuster new product, sales are anticipated to increase 50 percent next year (2020), even though the new product will come online in midyear. An additional 80 percent increase in sales is expected the following year (2021).
Transcribed Image Text:Pharma Biotech Corporation The Pharma Biotech Corporation spent several years working on developing a DHA product that can be used to provide a fatty-acid supplement to a variety of food products. DHA stands for docosahexaenoic acid, an omega-3 fatty acid found naturally in cold-water fish. The benefits of fatty fish oil have been cited in studies of the brain, the eyes, and the immune system. Unfortunately, it is difficult to consume enough fish to get the benefits of DHA, and most individuals might be concerned about the taste consequences associated with adding fatty fish oil to eggs, ice cream, or chocolate candy. To counter these constraints, Pharma Biotech and several competitors have been able to grow algae and other plants that are rich in DHA. The resulting chemical compounds then are used to enhance a variety of food products. Pharma Biotech's initial DHA product was designed as an additive to dairy products and yogurt. For example, the venture's DHA product was added to cottage cheese and fruit-flavored yogurts to enhance the health benefits of those products. After the long product development period, Pharma Biotech began operations in 2018. Income statement and balance sheet results for 2019, the first full year of operations, have been prepared. Pharma Biotech, however, is concerned about forecasting its financial statements for next year because it is uncer- tain about the amount of additional financing for assets that will be needed as Pharma Biotech Corporation the venture ramps up sales. Pharma Biotech expects to introduce a DHA product that can be added to chocolate candies. Not only will consumers get the satisfaction of the taste of the chocolate candies, but they will also benefit from the DHA enhancement. Because this is anticipated to be a blockbuster new product, sales are anticipated to increase 50 percent next year (2020), even though the new product will come online in midyear. An additional 80 percent increase in sales is expected the following year (2021).
PHARMA BIOTECH CORPORATION INCOME STATEMENT FOR DECEMBER 31, 2019 (THOUSANDS OF DOLLARS) Sales 15,000 Operating expenses - 13,000 ЕBIT 2,000 Interest - 400 EBT 1,600 Taxes (40% rate) -640 Net income 960 Cash dividends (40% payout) Added retained earnings -384 576 BALANCE SHEET AS OF DECEMBER 31, 2019 (THOUSANDS OF DOLLARS) Cash and marketable securities $ 1,000 Accounts payable $ 1,600 Accounts receivable 2,000 Bank loan 1,800 Inventories 2,200 Accrued liabilities 1,200 Total current assets 5,200 Total current liabilities 4,600 Long-term debt 2,200 Common stock 2,400 Fixed assets, net 6,800 Retained earnings 2,800 Total assets $12,000 Total liabilities and equity $12,000
Transcribed Image Text:PHARMA BIOTECH CORPORATION INCOME STATEMENT FOR DECEMBER 31, 2019 (THOUSANDS OF DOLLARS) Sales 15,000 Operating expenses - 13,000 ЕBIT 2,000 Interest - 400 EBT 1,600 Taxes (40% rate) -640 Net income 960 Cash dividends (40% payout) Added retained earnings -384 576 BALANCE SHEET AS OF DECEMBER 31, 2019 (THOUSANDS OF DOLLARS) Cash and marketable securities $ 1,000 Accounts payable $ 1,600 Accounts receivable 2,000 Bank loan 1,800 Inventories 2,200 Accrued liabilities 1,200 Total current assets 5,200 Total current liabilities 4,600 Long-term debt 2,200 Common stock 2,400 Fixed assets, net 6,800 Retained earnings 2,800 Total assets $12,000 Total liabilities and equity $12,000
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 2 steps with 1 images

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer
Knowledge Booster
Financial Policy and Growth
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Essentials Of Investments
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
FUNDAMENTALS OF CORPORATE FINANCE
FUNDAMENTALS OF CORPORATE FINANCE
Finance
ISBN:
9781260013962
Author:
BREALEY
Publisher:
RENT MCG
Financial Management: Theory & Practice
Financial Management: Theory & Practice
Finance
ISBN:
9781337909730
Author:
Brigham
Publisher:
Cengage
Foundations Of Finance
Foundations Of Finance
Finance
ISBN:
9780134897264
Author:
KEOWN, Arthur J., Martin, John D., PETTY, J. William
Publisher:
Pearson,
Fundamentals of Financial Management (MindTap Cou…
Fundamentals of Financial Management (MindTap Cou…
Finance
ISBN:
9781337395250
Author:
Eugene F. Brigham, Joel F. Houston
Publisher:
Cengage Learning
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Finance
ISBN:
9780077861759
Author:
Stephen A. Ross Franco Modigliani Professor of Financial Economics Professor, Randolph W Westerfield Robert R. Dockson Deans Chair in Bus. Admin., Jeffrey Jaffe, Bradford D Jordan Professor
Publisher:
McGraw-Hill Education
SEE MORE TEXTBOOKS